by Stephanie Reid, MD FRCPC
November 18, 2026
Autoimmune hepatitis is a long-lasting liver disease in which the body’s own immune system attacks the liver. It is not cancer, and it is not caused by a virus or by alcohol. Without treatment, the ongoing inflammation can scar the liver. With treatment, most people bring the disease under control and live a normal lifespan.
This article explains what autoimmune hepatitis is, how pathologists recognize it on a liver biopsy, and what the grade and stage in your report mean. It also describes the blood tests and treatments that accompany the diagnosis.
The immune system normally protects the body from infections. In an autoimmune disease, it mistakes the body’s own tissue for something foreign and attacks it. In autoimmune hepatitis, immune cells called lymphocytes and plasma cells attack the main cells of the liver, called hepatocytes. Hepatitis means inflammation of the liver.
Over time, the injured liver tries to heal by forming scar tissue, which pathologists call fibrosis. If the inflammation continues for years, the scarring can spread and lead to cirrhosis.
The cause of autoimmune hepatitis is not fully understood. It likely develops when a person with certain inherited immune system genes encounters an environmental trigger, such as an infection or a medication. In some people, a medication starts an illness that looks just like autoimmune hepatitis. Your doctor will review your medications for this reason.
Autoimmune hepatitis is not contagious and is not caused by anything a person did. People with autoimmune hepatitis are more likely to have other autoimmune conditions. Examples include celiac disease, autoimmune thyroid disease, and ulcerative colitis.
Autoimmune hepatitis is uncommon. Each year,r about 1 to 2 new cases are diagnosed for every 100,000 people, and about 11 to 25 of every 100,000 people are living with the disease. It can occur at any age, in children and adults of all backgrounds. Women are affected about three to four times as often as men.
Autoimmune hepatitis has traditionally been divided into two types based on the antibodies found in the blood. You may see these types in older reports.
Older articles also described a type 3, linked to antibodies against soluble liver antigen (anti-SLA). This antibody is now considered part of type 1. The European Association for the Study of the Liver (EASL) guidelines published in 2025 no longer separate the disease into types because they are treated the same way.
The symptoms of autoimmune hepatitis vary widely. Some people have no symptoms, and the disease is found because of abnormal liver enzymes on a routine liver blood test panel. Others feel tired, lose their appetite, or have joint pain or upper abdominal discomfort
Some people suddenly become unwell, with yellowing of the skin and eyes, called jaundice. In rare cases, the disease causes acute liver failure, which needs urgent care. About one in four people already has cirrhosis when the disease is first found, because it can be silent for years.
No single test proves autoimmune hepatitis. Doctors diagnose it by combining blood tests, a liver biopsy, and ruling out other liver diseases, such as viral hepatitis and drug injury.
Blood tests usually show raised liver enzymes called ALT and AST. Many people also have a high level of immunoglobulin G (IgG), an antibody made by plasma cells. Autoantibodies, such as the ones that define the types below, are tested as part of an autoimmune panel. A small number of people have typical biopsy findings but no autoantibodies.
A liver biopsy remains a standard part of the diagnosis. It shows the pattern of inflammation, helps rule out other diseases, and measures scarring before treatment starts. A biopsy may also be repeated later to check whether the inflammation has settled before reducing treatment.
When a pathologist examines a liver biopsy for autoimmune hepatitis, they look at where the inflammation sits and which cells it contains. The liver is organized around small channels called portal tracts, which carry blood vessels and bile ducts. The tissue between the portal tracts is called the lobule. Your report may describe some or all of the following features:
In 2022, an international group of liver pathologists published consensus criteria for these findings. A biopsy is considered typical of autoimmune hepatitis when it shows mainly portal inflammation with lymphocytes and plasma cells, with more than mild interface or lobular hepatitis. A second pattern, with mainly lobular inflammation, is also considered typical when it is accompanied by at least one portal finding. In both patterns, there must be no features that point to a different liver disease. Your report may describe the findings as likely, possible, or unlikely to represent autoimmune hepatitis.
The grade describes how active the inflammation is at the time of the biopsy. The pathologist looks at the amount of portal inflammation, interface hepatitis, and lobular inflammation. Your report may give the grade as a word (minimal, mild, moderate, or severe) or as a number. Some pathologists use the Batts-Ludwig system, which grades activity from 0 to 4. Others use the modified Ishak system, which gives a combined score from 0 to 18.
A high grade means the disease is very active. With treatment, the grade usually falls, and a later biopsy may show little or no inflammation. The grade can change quickly, so it describes the disease on the day of the biopsy.
The stage describes how much scarring is present. Scarring usually starts around the portal tracts and can spread into bands, called bridging fibrosis, that connect one part of the liver to another. The last stage is cirrhosis, in which scar tissue surrounds nodules of liver cells throughout the liver. Two staging systems are used most often:
The stage changes more slowly than the grade. Unlike the scarring in many other liver diseases, fibrosis in autoimmune hepatitis can partly improve when the inflammation is controlled for a long time.
Autoimmune hepatitis usually responds well to treatment. Depending on the population studied, about 76% to 100% of people reach remission, meaning their liver tests return to normal. In one cohort followed for many years, 96% of patients were alive at 10 years. Several studies have found that well-treated people live about as long as people of the same age and sex without the disease.
The main challenge is that autoimmune hepatitis is usually a lifelong condition. When treatment is stopped, the disease returns in about half to more than three-quarters of people. In a Dutch cohort, about 10% of people developed cirrhosis in the 10 years after diagnosis. People who already have cirrhosis are at higher risk of liver failure and hepatocellular carcinoma, a type of liver cancer.
After autoimmune hepatitis has been confirmed by pathology, treatment usually starts soon, because controlling the inflammation early protects the liver. A hepatologist, a doctor who specializes in the liver, usually leads care. Treatment follows guidelines such as the EASL Clinical Practice Guidelines published in 2025.
Because these medications suppress the immune system, your doctor will also review vaccinations, bone health, and side-effect screening. If cirrhosis is present, regular liver ultrasounds are used to check for early liver cancer.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name